Investigation of the effect of rivastigmine patch on gait disturbance in patients with Alzheimer disease. Clinical study (intervention study).

Investigation of the effect of rivastigmine patch on gait disturbance in patients with Alzheimer disease. Clinical study (intervention study). - Investigation of the effect of rivastigmine patch on gait disturbance in patients with Alzheimer disease. Clinical study (intervention study).

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025869

Enrollment

Registered

2017-02-15

Start date

2016-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease

Interventions

12 weeks Rivastigmine patch 9mg and 18mg onece daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Alzheimer disease

Exclusion criteria

Exclusion criteria: Patients with obvious motor disability Patients who can not administer rivastigmine patch

Design outcomes

Primary

Measure	Time frame
gait speed, gait speed on dual task at 4weeks and 12 weeks after therapy.	—

Countries

Japan

Contacts

Public ContactHideki Shimura

Juntendo University Urayasu Hospital Department of Neurology

miurashimura@yahoo.co.jp047-353-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026